| 5 | 1/1 | 返回列表 |
| 查看: 688 | 回復(fù): 8 | ||
| 本帖產(chǎn)生 1 個 博學(xué)EPI ,點擊這里進(jìn)行查看 | ||
| 當(dāng)前只顯示滿足指定條件的回帖,點擊這里查看本話題的所有回帖 | ||
zps1888銀蟲 (小有名氣)
|
[求助]
求職:文獻(xiàn)全文下載
|
|
|
各位大俠,查好后請發(fā) 郵箱 rmrrtv@126.com 查不全的也可以,好的話補發(fā)金幣哦 1 Chemistry and biology of cyclic depsipeptides of medicinal and biological interest 2 New drugs from the sea 3 Recent developments in depsipeptide research 4 Use of angiogenesis inhibitors in tumour treatment 5 New drugs in cancer therapy Chemotherapeutic Strategies in the Challenge of Cancer Treatment 6 Marine-derived anticancer agents in clinical trials 7 Effect of Aplidin in acute lymphoblastic leukaemia cells 8 Pharmaceutical development of anticancer agents derived from marine sources 9 Establishment and characterisation of a human carcinoma cell line with acquired resistance to Aplidin™ 10 Marine natural products and their potential applications as anti-infective agents 11 In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: 12 Marine natural products 13 Natural products in anticancer therapy 14 The discovery and development of marine compounds with pharmaceutical potential 15 In vitro hematotoxicity of Aplidine on human bone marrow and cord blood progenitor cells 16 Marine genetic resources: A review of scientific and commercial interest 17 In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells 18 Degradation kinetics of aplidine, a new marine antitumoural cyclic peptide, in aqueous solution 19 Novel anti-cancer agents in development: exciting prospects and new challenges 20 Marine organisms as a source of new anticancer agents 21 Bioanalysis of aplidine, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4′-hydrazino-2-stilbazole 22 Antitumor compounds from tunicates 23 Synthesis, Conformational Analysis, and Cytotoxicity of Conformationally Constrained Aplidine and Tamandarin A Analogues Incorporating a Spirolactam β-Turn Mimetic 24 Synthetic Studies of Tamandarin B Side Chain Analogues 25 Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials† 26 In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug 27 Drugs from the seas-current status and microbiological implications 28 Population pharmacokinetics meta-analysis of plitidepsin (Aplidin® in cancer subjects29 Nature: a vital source of leads for anticancer drug development |
木蟲 (著名寫手)
天堂里的惡魔
木蟲 (著名寫手)
木蟲之王 (文學(xué)泰斗)

銀蟲 (小有名氣)
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 352求調(diào)劑 +3 | 大米飯! 2026-03-22 | 3/150 |
|
|---|---|---|---|---|
|
[考研] 石河子大學(xué)(211、雙一流)碩博研究生長期招生公告 +3 | 李子目 2026-03-22 | 3/150 |
|
|
[考研] 北科281學(xué)碩材料求調(diào)劑 +6 | tcxiaoxx 2026-03-20 | 6/300 |
|
|
[考研] 298求調(diào)劑 +6 | 上岸6666@ 2026-03-20 | 6/300 |
|
|
[考研] 315分,誠求調(diào)劑,材料與化工085600 +3 | 13756423260 2026-03-22 | 3/150 |
|
|
[考研] 08工科 320總分 求調(diào)劑 +11 | 梨花珞晚風(fēng) 2026-03-17 | 11/550 |
|
|
[考研] 一志愿 西北大學(xué) ,070300化學(xué)學(xué)碩,總分287,雙非一本,求調(diào)劑。 +3 | 晨昏線與星海 2026-03-20 | 3/150 |
|
|
[考研] 286分人工智能專業(yè)請求調(diào)劑愿意跨考! +4 | lemonzzn 2026-03-17 | 8/400 |
|
|
[考研] 初試 317 +7 | 半拉月丙 2026-03-20 | 7/350 |
|
|
[考研] 306求0703調(diào)劑一志愿華中師范 +5 | 紙魚ly 2026-03-21 | 5/250 |
|
|
[考研] 一志愿重慶大學(xué)085700資源與環(huán)境總分308求調(diào)劑 +7 | 墨墨漠 2026-03-20 | 7/350 |
|
|
[考研] 083200學(xué)碩321分一志愿暨南大學(xué)求調(diào)劑 +3 | innocenceF 2026-03-17 | 3/150 |
|
|
[考研] 一志愿華中科技大學(xué),080502,354分求調(diào)劑 +5 | 守候夕陽CF 2026-03-18 | 5/250 |
|
|
[考研]
|
.6lL 2026-03-18 | 8/400 |
|
|
[考研] 考研調(diào)劑求學(xué)校推薦 +3 | 伯樂29 2026-03-18 | 5/250 |
|
|
[考研] 中南大學(xué)化學(xué)學(xué)碩337求調(diào)劑 +3 | niko- 2026-03-19 | 6/300 |
|
|
[考研] 工科材料085601 279求調(diào)劑 +7 | 困于星晨 2026-03-17 | 9/450 |
|
|
[考研] 085601材料工程專碩求調(diào)劑 +10 | 慕寒mio 2026-03-16 | 10/500 |
|
|
[考研] 301求調(diào)劑 +4 | A_JiXing 2026-03-16 | 4/200 |
|
|
[考研] 考研調(diào)劑 +3 | 淇ya_~ 2026-03-17 | 5/250 |
|